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Abstract
Background: Drug resistance is the outcome of multiple-gene interactions in cancer cells under stress of anticancer 
agents. MDR1 overexpression is most commonly detected in drug-resistant cancers and accompanied with other gene 
alterations including enhanced glucosylceramide synthase (GCS). MDR1 encodes for P-glycoprotein that extrudes 
anticancer drugs. Polymorphisms of MDR1 disrupt the effects of P-glycoprotein antagonists and limit the success of 
drug resistance reversal in clinical trials. GCS converts ceramide to glucosylceramide, reducing the impact of ceramide-
induced apoptosis and increasing glycosphingolipid (GSL) synthesis. Understanding the molecular mechanisms 
underlying MDR1 overexpression and how it interacts with GCS may find effective approaches to reverse drug 
resistance.
Results: MDR1 and GCS were coincidently overexpressed in drug-resistant breast, ovary, cervical and colon cancer cells; 
silencing GCS using a novel mixed-backbone oligonucleotide (MBO-asGCS) sensitized these four drug-resistant cell 
lines to doxorubicin. This sensitization was correlated with the decreased MDR1 expression and the increased 
doxorubicin accumulation. Doxorubicin treatment induced GCS and MDR1 expression in tumors, but MBO-asGCS 
treatment eliminated "in-vivo" growth of drug-resistant tumor (NCI/ADR-RES). MBO-asGCS suppressed the expression 
of MDR1 with GCS and sensitized NCI/ADR-RES tumor to doxorubicin. The expression of P-glycoprotein and the 
function of its drug efflux of tumors were decreased by 4 and 8 times after MBO-asGCS treatment, even though this 
treatment did not have a significant effect on P-glycoprotein in normal small intestine. GCS transient transfection 
induced MDR1 overexpression and increased P-glycoprotein efflux in dose-dependent fashion in OVCAR-8 cancer cells. 
GSL profiling, silencing of globotriaosylceramide synthase and assessment of signaling pathway indicated that GCS 
transfection significantly increased globo series GSLs (globotriaosylceramide Gb3, globotetraosylceramide Gb4) on 
GSL-enriched microdomain (GEM), activated cSrc kinase, decreased β-catenin phosphorylation, and increased nuclear 
β-catenin. These consequently increased MDR1 promoter activation and its expression. Conversely, MBO-asGCS 
treatments decreased globo series GSLs (Gb3, Gb4), cSrc kinase and nuclear β-catenin, and suppressed MDR-1 
expression in dose-dependent pattern.
Conclusion: This study demonstrates, for the first time, that GCS upregulates MDR1 expression modulating drug 
resistance of cancer. GSLs, in particular globo series GSLs mediate gene expression of MDR1 through cSrc and β-catenin 
signaling pathway.
Background
Chemotherapy is the principal treatment option for
patients with late stage cancers. Despite considerable
advances in drug discovery, metastatic solid malignancies
remain incurable, due to their poor response to most of
the conventional antineoplastic agents. Acquired drug
resistance of cancer cells severely limits the success of
chemotherapy, particular in solid tumors [1,2]. The
ABCB1 transporter, known as P-glycoprotein (P-gp) is
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encoded by human multidrug resistance 1 gene (MDR1)
and is an important mediator of drug resistance [2,3].
Like other membrane transport proteins in ABC (ATP
binding cassette) family, P-gp is found in various cellular
membranes of organisms from bacteria to mammals. P-
gp plays roles in the absorption, distribution, and excre-
tion of pharmacological compounds in normal tissues
[4,5]. However, overexpression of MDR1  in tumors
results in increase of P-gp and active effluxing of a variety
of natural product anticancer agents from cells [2,6]. The
polymorphism of MDR1, particularly the 'silent' poly-
morphism, blocks the effects of currently available P-gp
antagonists and thus limits the success of these agents in
clinical trials [7-10].
Drug resistance is the outcome of multiple-gene inter-
actions in cancer cells under the stress of antineoplastic
agents. Several drug-resistant markers including Bcl-2,
mutant p53, and glucosylceramide synthase (GCS) are
overexpressed in drug-resistant cancers [5,11-13]. How-
ever, little is known about the molecular mechanism
underlying  MDR1  overexpression and how it interacts
with other genes to impart drug-resistance. Recently, an
emerging body of evidence indicates a curious associa-
tion of multidrug resistance with ceramide glycosylation
[13-18]. GCS (UDP-glucose:ceramide glucosyltrans-
ferase, UGCG) transfers a glucose residue from UDP-glu-
cose to ceramide and produces glucosylceramide [19,20].
This first step in glycosphingolipid (GSL) synthesis tightly
regulates the production of all upstream GSLs [21]. Cer-
amide, a lipid second messenger, induces growth arrest or
apoptosis in cancer cells; this induced-apoptosis is in part
responsible for the therapeutic efficiency of antineoplas-
tic regimens including anthracyclines, taxanes, and vinca
alkaloids and radiation therapy [15,22-25]. Overexpres-
sion of GCS can result in drug resistance, as introduction
of GCS confers cell resistance to doxorubicin, daunorubi-
cin, and tumor necrosis factor-α [16,26,27]. GCS is over-
expressed in many MDR cancer cell lines [17,28], and in
leukemia, breast cancer, and renal cell cancer [29-31].
Interestingly, GCS is coincidently overexpressed with
MDR1 in drug-resistant cells [28,32] and in leukemia cells
from patients who have poor-response to chemotherapy
[31,33]. We have studied the effects of ceramide glycosy-
lation on MDR1 and found that GCS upregulates MDR1
expression through activation of cSrc and β-catenin sig-
naling.
Results
Silencing GCS represses MDR1 expression and sensitizes 
cancer cells to chemotherapeutic agents
We observed the role of GCS in the regulation of MDR1
expression in NCI/ADR-RES and its GCS transfectants.
GCS protein levels were increased in NCI/ADR-RES/
GCS cells and significantly decreased in NCI/ADR-RES/
asGCS cells (Figure 1A). Consistent with these, GCS
enzyme activity was decreased to 52% (0.9 vs. 1.7 GC/
Cer) in NCI/ADR-RES/asGCS cells, whereas the activity
was increased to 110% (1.9 vs. 1.7 GC/Cer) in NCI/ADR-
R E S / G C S ,  a s  c o m p a r e d  w i t h  p a r e n t a l  N C I / A D R - R E S
cells (Figure 1A,B). Coordinately, P-gp was significantly
decreased to 40% in NCI/ADR-RES/asGCS cells, as
detected by Western blotting and immunostaining (Fig-
ure 1A,C). HPLC assays indicated that cellular accumula-
tion of doxorubicin was increased by 3-fold in NCI/ADR-
RES/asGCS cells (2.54 ± 0.15 vs. 0.80 ± 0.51 ng/105 cells)
as compared with NCI/ADR-RES cells (Figure 1D). Sub-
stantial intracellular accumulation of doxorubicin was
also observed in NCI/ADR-RES/asGCS cells under fluo-
rescence microscopy (Figure 1D).
MDR1 and GCS have been shown to be coincidently
overexpressed in several drug-resistant cell lines [17,28].
To validate the association of MDR1  expression with
GCS, we assessed MDR1  expression in four different
types of cancer cells, in the absence and presence of GCS
silencing with MBO-asGCS (a mixed-backbone oligonu-
cleotide against human GCS) [34,35]. Results showed
that GCS protein levels were decreased to 40%, 45%, 56%
and 20% of control, respectively in drug-resistant human
A2780-AD ovary cancer, KB-A1 cervical cancer, SW620/
AD colon cancer, and murine EMT6/AR1 breast cancer
cells treated with MBO-asGCS (50 nM, 7 days) (Figure
2A). Consistently, MBO-asGCS treatments decreased P-
gp protein levels to 10%, 5%, 2% and 20% of control in
these cell lines. Furthermore, MBO-asGCS substantially
sensitized cells to doxorubicin; the EC50 values for doxo-
rubicin were decreased by 4-fold in A-2780AD, 43-fold in
KB-A1, 7-fold in SW620/AD, and 6-fold in EMT6/AR1
cells, respectively (Figure 2B). These data indicate that
suppressing GCS can repress MDR1  expression and
reverse cellular resistance to anticancer agents.
Silencing GCS represses MDR1 expression and restores 
tumor sensitivity to doxorubicin
Inoculation of NCI/ADR-RES cells into athymic mice
generated MDR tumor xenografts. Mice with MDR xeno-
grafts were treated with MBO-asGCS (1 mg/kg per 3
days) alone or combined with doxorubicin (2 mg/kg per
week). As shown in Figure 3A, MBO-asGCS treatment
significantly decreased tumor growth and increased the
sensitivity of these tumors to doxorubicin. The combina-
tion treatment (MBO-asGCS + Dox) decreased tumor
volumes to 45% (187 vs. 411 mm3, p < 0.01) and 20% (187
vs. 913 mm3, p < 0.001), respectively, as compared with
doxorubicin or saline treatment. Western blot analysis
revealed that GCS and P-gp protein levels were increased
2-fold and 4-fold in tumors treated with doxorubicin, as
compared with saline (Figure 3B). However, MBO-asGCS
decreased both GCS and P-gp protein levels by approxi-Liu et al. Molecular Cancer 2010, 9:145
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mately 4-fold in tumors treated with MBO-asGCS alone
o r  M B O - a s G C S  c o m b i n e d  w i t h  d o x o r u b i c i n ,  a s  c o m -
pared with saline and doxorubicin groups (Figure 3B).
These findings were confirmed in tumor tissues after
immunostaining for GCS and P-gp (Figure 3C).
In agreement with its repressive effect on P-gp protein,
MBO-asGCS significantly increased doxorubicin accu-
mulation in tumor tissues. As shown in Figure 4A, MBO-
asSGCS treatment augmented tumor accumulation of
doxorubicin by 8-fold (78 pg/mg vs. 10 pg/mg) and 2-fold
(59 pg/mg vs. 28 pg/mg) after 4 and 24 hrs of doxorubicin
administration, compared to the saline group, respec-
tively. Meanwhile, serum levels of doxorubicin decreased
in the MBO-asGCS group. Further assessment using
Flutax-2 (Oregon green 488-paclitaxel, a substrate of the
P-gp pump) revealed that paclitaxel accumulation was
increased 4-fold (11.41% vs. 3.32% of total, p < 0.001, Fig-
ure 4B), since that paclitaxel efflux decreased by 8-fold
Figure 2 Silencing of GCS by MBO-asGCS Represses MDR1 Expression and Sensitizes Drug-Resistant Cancer Cells. (A) P-gp and GCS in drug-
resistant cancer cells. Cells were cultured in growth medium for 24 hr, and then treated with vehicle or MBO-asGCS (50 nM) for an additional 48 hr. 
Equal amounts of protein (50 μg/lane) were resolved by 4-20% gradient SDS-PAGE and immunoblotted with anti-GCS and anti-P-gp antibodies. GAP-
DH was used as endpoint control, and GCS/GAPDH or P-gp/GAPDH represents optical densities of the bands. -, vehicle (Lipofectamine 2000); +, MBO-
asGCS (50 nM). *, p < 0.001 compared with vehicle treatment. (B) Cell response to doxorubicin. After pretreatment of MBO-asGCS (50 nM) or vehicle, 
cells were incubated with 5% FBS medium at the presence of doxorubicin for an additional 72 hr. *, p < 0.001 compared with vehicle.
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compared to doxorubicin treatment (solid squares). (B) Western blots of tumor tissues. After treatments, extracted tumor proteins (100 μg/μl, three 
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(1.66% vs. 13.2% of accumulated, p < 0.001) in tumors
treated with MBO-asGCS (Figure 4C). MBO-asGCS
treatments did not have a significant effect on P-gp of
normal small intestine. These results indicate that silenc-
ing GCS by MBO-asGCS efficiently represses MDR1
expression and reverses in vivo drug resistance.
GCS upregulates MDR1 expression through cSrc kinase and 
β-catenin signaling
We transiently transfected GCS in human OVCAR-8
ovarian carcinoma cells, which express low level of MDR1
[36], in order to explore putative mechanisms underlying
GCS upregulation of MDR1. One week after the transfec-
tion, GCS protein levels were elevated by 10-fold, 20-fold
and 25-fold in cells transfected with increasing amounts
of GCS plasmid DNA (2, 4, and 8 μg/dish) (Figure 5A).
Interestingly, the levels of phosphorylated cSrc and FAK
proteins were enhanced corresponding to GCS levels,
even though the total cSrc levels remained relatively
unchanged. Nuclear β-catenin levels were elevated by 5-
to 10-fold whereas phosphorylated β-catenin declined as
GCS, p-cSrc, and p-FAK increased in these cells (at 4, and
8 μg/dish). P-gp protein levels were elevated by 2 to 3-fold
concomitant with MDR1 promoter activities in these cells
(4 and 8 μg/dish) (Figure 5B). The pyrazolo pyrimidine
(PP2), a Src kinase inhibitor [37,38] selectively decreased
the levels of phosphorylated cSrc (not p-FAK) and
increased phosphorylated β-catenin, but did not decrease
Gb3 synthase of cells after GCS transfection (8 mg/dish,
Figure 5A). The PP2 treatments blocked the stimulation
effect of GCS on nuclei β-catenin, further MDR1  pro-
moter activity and P-gp expression (Figure 5A,B). We also
assessed the cellular accumulation and activity of P-gp
using Flutax-2. As shown in Figure 5C, paclitaxel accu-
mulation was decreased to 60% and 47% of control in
cells transfected with increasing amounts of GCS plasmid
(4, 8 μg DNA/dish), respectively, as compared with mock
transfection. Conversely, cell efflux of paclitaxel was ele-
vated to 153% and 212% over control in these transfec-
tants. Inhibition of cSrc kinase by PP2 treatment
eliminated the effects of GCS transfection on P-gp activ-
ity in the accumulation and efflux of paclitaxel (Figure
5C).
Silencing GCS represses MDR1 transactivation via 
inhibition of cSrc and β-catenin signaling
We silenced GCS with MBO-asGCS in NCI/ADR-RES
cells that overexpressed GCS and MDR1, to verify the
mechanism underlying GCS modulation of MDR1. After
one week of MBO-asGCS treatments, GCS protein levels,
but neither GD3 synthase nor Gb3 synthase, were
decreased to 30%, 5% and 2% in cells treated with increas-
ing concentrations of MBO-asGCS (50, 100, 200 nM), as
compared with vehicle control, respectively (Figure 6A).
The levels of the phosphorylated cSrc and FAK proteins,
but not the total cSrc, were correspondingly decreased
with GCS protein levels. Interestingly, nuclear β-catenin
was decreased to approximately 10%, whereas phospho-
rylated β-catenin was increased as the levels of GCS, p-
cSrc, and p-FAK were decreased in these cells after
MBO-asGCS treatments. P-gp protein levels were
decreased to 85%, 30% and 25% with decreases in MDR1
promoter activity of cells treated with increasing concen-
trations of MBO-asGCS (50, 100, 200 nM) (Figure 6B).
Figure 4 Effects of GCS Silencing on P-gp Regulated Drug Accumulation and Efflux in Tumors. NCI/ADR-RES tumors were treated with MBO-
asGCS (1 mg/kg/3 days, 3 mice/group) or saline for 7 days. (A) Doxorubicin accumulation. After 4 hr and 24 hr peritoneal administration of doxorubicin 
(1 mg/kg), serum and tumor tissues were collected and prepared for HPLC assays. Doxorubicin levels were represented per μl of serum or per mg of 
tumor tissue. *, p < 0.001 compared with serum of saline treatment at 24 hr; **, P < 0.001 compared with saline treatments. (B) Paclitaxel accumulation. 
After two administrations of MBO-asGCS, tissue suspensions (25 mg/reaction) were incubated with Flutax-2 (1 μM) in medium containing collagenase 
IV, immediately following mincing. Accumulation of paclitaxel was measured after 2 hr incubation. *, p < 0.001 compared with saline treatment of 
tumors. (C) Paclitaxel efflux. After accumulation described in (B), tissues were incubated with fresh medium for an additional 2 hr to measure paclitaxel 
efflux. *, p < 0.001 compared with saline treatment of tumors.
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Sequentially, we found that cellular accumulation of
paclitaxel was elevated by 2.5-fold, 11-fold and 22-fold in
cells treated with MBO-asGCS, compared to vehicle con-
trol, respectively (Figure 6C). Conversely, cell efflux of
paclitaxel was reduced to 89%, 48%, and 31% in cell after
these treatments. As anticipated, verapamil treatment (10
μM) inhibited P-gp function, as effectively as MBO-
asGCS (50 nM) in the cellular accumulation and efflux of
paclitaxel in NCI/ADR-RES cells (Figure 6C).
Globo series GSLs modulate MDR1 expression
It has been reported that glycosphingolipids-enriched
microdomains (GEMs) or rafts on cell membranes can
mediate cSrc kinase activation [39-41]. To clarify which
GSL has a major role in mediating MDR1 expression, we
analyzed GSL profiles of NCI/ADR-RES variants. It was
found that the levels of globo series GSLs including glo-
botriaosylceramide (Gb3) and globotetraosylceramide
(Gb4) were significantly increased in NCI/ADR-RES/
GCS cells and decreased in NCI/ADR-RES/asGCS cells
(Figure 7A). On the other hand, N-acetylneuraminyl-
α2,3-galactosyl-β1,4-glucosyl ceramide (GM3) and N-
acetylgalactosaminyl-β1,4-(α2,3N-acetylneuraminyl)
galactosyl-β1,4-glucosyl ceramide (GM2) were increased
in NCI/ADR-RES/asGCS cells. As a receptor for verocy-
totoxin, the levels of Gb3 on cells are associated with the
cytotoxicity of verocytotoxin [42-44]. To assess the levels
of Gb3 in NCI/ADR-RES variants, we examined cell via-
bility in response to verocytotoxin. As shown in Figure
7B, NCI/ADR-RES/asGCS cells were substantially resis-
tant, while NCI/ADR-RES/GCS cells were extremely sen-
sitive to verocytotoxin. The EC50 for verocytotoxin was
increased by 4,000-fold (8 × 102 vs. 2 × 10-1 ng/ml) in
NCI/ADR-RES/asGCS cells and was decreased by 400-
fold (2 × 10-1 vs. 5 × 10-4 ng/ml) in NCI/ADR-RES/GCS
cells.
Furthermore, we examined whether GCS alter Gb3
concentration and cSrc kinase in GEMs. As shown in Fig-
ure 7C and 7D, silencing of GCS by MBO-asGCS (100
nM) significantly decreased Gb3 level, and p-cSrc to 32%
in GEMs of NCI/ADR-RES cells. On the contrary, GCS
transfection significantly increased Gb3 and doubled p-
cSrc in GEMs of OVCAR-8 cells. Alterations of Gb3 and
cSrc kinase in GEMs following GCS gene manipulations
significantly changed P-gp expression levels as well.
In order to characterize the role of GSLs in MDR1
expression, we selectively silenced the enzyme responsi-
ble for the synthesis of globo series GSLs. Cells were
Figure 5 GCS Upregulates MDR1 Expression through Enhanced cSrc/β-Catenin Signaling. After a series of transient GCS transfection (0, 2.0, 4.0, 
8.0 μg of pcDNA 3.1-GCS plasmid DNA in 100-mm dish), OVCAR-8 cells were cultured in 10% FBS RPMI-1640 medium for 7 days. OVCAR-8 cells trans-
fected with pcDNA 3.1-GCS (8 μg) were then treated with 10 μM PP2 for 24 hr (+PP2). (A) Western blots. Equal amounts of detergent-soluble total 
cellular proteins or nuclear proteins (50 μg/lane) were resolved on 4-20% gradient SDS-PAGE and immunoblotted with indicated primary antibodies. 
Gb3 syn, Gb3 synthase; p-cSrc, phosphorylated cSrc; p-FAK, phosphorylated FAK; p-β-catenin, phosphorylated β-catenin. (B) MDR1 expression. MDR1 
promoter activity (top panel) and P-gp protein (bottom panel) were assessed as described in Methods, after 7 days of GCS transient transfection in 
OVCAR-8 cells. *, p < 0.001 compared with mock transfection; **, p < 0.001 compared with vehicle treatment in cells transfected with GCS (8 μg DNA). 
(C) Paclitaxel accumulation and efflux. Cells were incubated with Flutax-2 (0.5 μM) in medium at 37°C. Accumulation of paclitaxel (top panel) was mea-
sured after 2 hr incubation. After washing with ice-cold PBS, cells were re-incubated with fresh medium for an additional 2 hr to measure efflux (bot-
tom panel). *, p < 0.001 compared with the mock transfection. **, p < 0.001 compared with vehicle treatment in cells transfected with GCS (8 μg DNA).
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transfected with siRNA against Gb3 synthase to block
globo series GSL production. As shown in Figure 8A,
silencing Gb3 synthase significantly decreased MDR1
promoter activity, particularly in NCI/ADR-RES/GCS
cells (p < 0.001, compared with NCI/ADR-RES cells).
Consistently, silencing of Gb3 synthase considerably
decreased p-cSrc, β-catenin and P-gp protein levels and
efflux in both cell lines, as detected in Western blot (Fig-
ure 8B), cellular efflux (Figure 8C) and immunostaining
(Figure 8D). We further treated NCI/ADR-RES cells with
FH535, inhibiting β-catenin recruitment to T-cell factor
(Tcf) [45]. We found that FH535 (20 μM) decreased P-gp
protein to 25% of control (Figure 8E); however, it did not
affect either Gb3 synthase or p-cSrc in Western blotting.
Discussion
GCS is a key enzyme for ceramide glycosylation and GSL
synthesis. This study demonstrates that GCS upregulates
MDR1 expression and modulates drug resistance of can-
cer. It reveals that GSLs, in particular globo series GSLs
mediate gene expression through cSrc and β-catenin sig-
naling.
Previous works indicate that GCS and MDR1 are co-
overexpressed in drug-resistant leukemia [33] and in
drug-resistant cancer cells including human ovarian can-
cer (NCI/ADR-RES), cervical cancer (KB-V1), leukemia
(HL-60/VCR), melanoma (MeWo Eto) and colon cancer
(SW620/AD) [13,28]. However, it is not clear how GCS or
MDR1 affects each other to promote drug-resistance.
Suppressing GCS with siRNA or a GCS inhibitor, 1-phe-
nyl-2-decanoylamino-3-morpholino-1-propanol
(PDMP), down-regulates the expression and function of
P-gp in human breast cancer cells [18]; however, inhibi-
tion of GCS by other types of GCS inhibitors (N-butyl-
deoxygalactonojirimycin, OGB-1; N-nonyl-deoxygalac-
tonojirimycin, OGB2) did not appear to have any effect
on P-gp functional activity in chronic lymphocytic leuke-
mia cells, even though OGB-1 and OGB2 sensitized these
cells [46]. P-pg has been proposed as a Golgi glucosylcer-
amide flippase that enhances neutral GSL synthesis, since
transfection of MDR1 increases globo series GSLs, and
inhibition of P-gp with cyclosporine A decreases neutral
GSL biosynthesis in cells [32,44,47,48]. To characterize
the role of GCS in MDR1-GCS co-overexpression, we
tested P-gp expression after GCS gene silencing in several
different types of cancer cells and in tumors. We have
found that silencing of the GCS down-regulates P-gp
expression, inhibits its efflux activity, and consequently
sensitizes MDR cells including NCI/ADR-RES, A2780-
AD, KB-A1, SW620/AD and EMT6/AR1 (Figure 1, 2).
Furthermore, suppressing GCS with MBO-asGCS sub-
stantially decreases P-gp protein, enhances the accumula-
Figure 6 Silencing GCS Represses MDR1 Expression by Decreasing cSrc/β-Catenin Signaling. After MBO-asGCS treatments (0, 50, 100, 200 nM), 
drug resistant NCI/ADR-RES cells were cultured in 10% FBS RPMI-1640 medium for 7 days. The NCI/ADR-RES cells were incubated with verapamil (10 
μg, 2 hr) in 5% FBS RPMI-1640 medium to inhibit P-gp function. (A) Western blots. Equal amounts of total cellular proteins or nuclear proteins (50 μg/
lane) were resolved by 4-20% gradient SDS-PAGE and immunoblotted with indicated primary antibodies. GD3 syn, GD3 synthase; Gb3 syn, Gb3 syn-
thase; p-cSrc, phosphorylated cSrc; p-FAK, phosphorylated FAK; p-β-catenin, phosphorylated β-catenin. (B) MDR1 expression. MDR1 promoter activity 
(top panel) and P-gp protein (bottom panel) were assessed as described in Methods, after 7 days of MBO-asGCS treatments. *, p < 0.001 compared 
with vehicle. (C) Paclitaxel accumulation and efflux. Cells were incubated with Flutax-2 (0.5 μM) in medium at 37°C for 2 hr to measure paclitaxel ac-
cumulation (top panel). After washing with ice-cold PBS, cells were incubated with fresh medium for an additional 2 hr to measure paclitaxel efflux 
(bottom panel). *, p < 0.001 compared with vehicle treatment.
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tion of doxorubicin or paclitaxel, and sensitizes tumors to
chemotherapy (Figure 3, 4). We have reported that doxo-
rubicin upregulates GCS expression and results in drug
resistance in cells [17]. Herein it has been found that dox-
orubicin treatment up-regulates GCS expression and
importantly, P-gp expression in tumors (Dox vs. saline,
Figure 3B); MBO-asGCS simultaneously suppresses GCS
and MDR1 overexpression (MBO-asGCS vs. saline, Fig-
ure 3B), even under doxorubicin challenge (MBO-asGCS
+ Dox vs. Dox, Figure 3B). Taken together, these results
demonstrate that GCS has a regulatory role in MDR1
expression and genesis of drug resistance. Inhibition of
GCS appears to be an efficient approach not only to pre-
vent the formation of drug resistance during the course of
cancer chemotherapy, but also to reverse drug resistance
of cancers.
It has taken time to understand how GSLs generated by
GCS modulate gene expression. By introducing GCS into
OVCAR-8 cells that express low levels of GCS and P-gp,
we have found that GCS consequently upregulates MDR1
expression and enhances P-gp efflux through cSrc and β-
catenin signaling. Inhibition of Src kinase by PP2 further
indicates that GSLs in cell membrane may mediate the
phosphorylation of cSrc and of β-catenin that decreases
β-catenin levels in the nucleus (Figure 5). This finding has
been confirmed by selective silencing of GCS (not Gb3
synthase or GD3 synthase) using MBO-asGCS, in NCI/
ADR-RES cells that over express GCS and P-gp (Figure
6). The promoter of the human MDR1 contains multiple
Tcf4/LEF (T-cell factor 4/lymphoid enhancer factor)
binding motifs, CTTTGA/TA/T [49,50]. It has been dem-
onstrated that MDR1  i s  a  d i r e c t  t a r g e t  g e n e  o f  t h e  β -
Figure 7 Globo Series GSLs Mediate MDR1 Transactivation. (A) Glycosphingolipids. Cells were cultured in 10% FBS RPMI-1640 medium and har-
vested by trypsin-EDTA. Extracted lipids (5 μl aliquot of 100 μl) were resolve by TLC and GSLs were visualized by spraying with diphenylamine-aniline 
phosphoric acid reagent. GlcCer, glucosylceramide. (B) Gb3, a receptor of verocytotoxin on GCS transfectants. Cells were incubated with increasing 
concentrations of verocytotoxin in 5% FBS RPMI-1640 medium for 72 hr. *, p < 0.001 compared to ADR-RES. (C) GEM GSLs. GEMs of cells were prepared 
with gradient sucrose and extracted lipids (100 μg of GEM protein) were applied to HPTLC plates. (D) cSrc phosphorylation in GEMs. Equal amounts 
of GEM protein (50 μg/lane) were resolved by 4-12% gradient SDS-PAGE and immunoblotted with antibodies. p-cSRc/cSrc represents optical densities 
of the bands; *, p < 0.001 compared with mock.
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catenin/Tcf4 transcriptional complex, and activation of
β-catenin increases P-gp expression [51-53]. It has been
reported that active cSrc elevates the levels of β-catenin,
and inhibition of cSrc decreases the binding of β-catenin
to the promoters of β-catenin/Tcf4 complex targets such
as cyclin D1 and c-Myc [54,55]. In present study, inhibi-
tions of cSrc kinase by PP2 and β-catenin/T cf4 recruit-
ment by FH535 sequentially prevent MDR1
transactivation (Figure 5, 6, 8). These data strongly sup-
port the model that GCS enhances cSrc signaling and β-
catenin, and transactivates MDR1 expression.
GCS is the rate-limiting enzyme in GSL synthesis. Glu-
cosylceramide, the product of GCS, is further converted
to lactosylceramide (Galβ1-4GlcCer) by lactosylceramide
synthase (glucosylceramide 1,4-galactosyltransferase).
Lactosylceramide is the common precursor of nearly all
the neutral GSLs and gangliosides. GSL profiling and
selective silencing of Gb3 synthase indicate that globo
series GSLs (Gb3, Gb4) have more important role than
ganglioside in mediating MDR1  transactivation and
expression (Figure 7, 8). GSLs in either tumor cells or
normal cells are clustered and assembled with specific
membrane proteins and signal transducers to form GSL-
enriched microdomains (GEMs) or rafts [39,56,57]. Gb3
(defined as CD77) is associated with Src family Yes kinase
on GEMs [58]. Shiga toxin binds to its receptor Gb3, and
activates cSrc kinase [59,60]. Stimulation of monosialyl-
Gb5 by its antibody RM1 activates cSrc on GEMs and
increases β-catenin in MCF-7 cells [39]. AdamantylGb3,
a water-soluble Gb3 mimic significantly increases MDR1
expression [61]. Inhibition of GCS by D-PDMP indicates
Globo series of GSLs are required for Src kinases that are
associated with and concentrated on GEMs [62]. In this
study we have found that introduction of GCS or silenc-
ing of GCS significantly increases or decreases the levels
of Gb3 in en tire ce lls, and particular in GEMs (F igure
7A,B,C). Gb3 levels affect cSrc kinase and result in p-cSrc
alterations in GEMs, and consequentially P-gp expression
(Figure 7). Taken together, we propose that GCS regulates
MDR1  expression through activation of cSrc and β-
catenin signaling, as depicted in Figure 9. Overexpression
of GCS produces large amounts of glucosylceramide
when cancer cells are under chemotherapy stress.
Enhancement of globo series GSLs (Gb3, Gb5, MSGb5)
Figure 8 Gb3 Synthesis and β-Catenin Recruitment Are Involved in MDR1 Transactivation. To silence Gb3 synthase, cells were transfected with 
siRNA-Gb3S (100 nM) or control siRNA (siRNA-SC) twice and grown in 10% FBS RPMI-1640 medium for 7 days. (A) MDR1 promoter activity. *, P < 0.001 
compared with siRNA-SC. (B) Western blot. Gb3 syn, Gb3 synthase; p-cSrc, phosphorylated cSrc. (C) Cellular efflux. *, p < 0.001 compared with siRNA-
SC. (D) Immunostaining. Cells were incubated with anti-human Gb3 synthase (red) and anti-P-gp (green) following addition of Alexa 667- and Alexa 
488-conjugated secondary antibodies. DAPI in mounting solution was used for nucleus counterstaining (blue). Fluo., merged fluorescence micropho-
tograph (x 200). (E) β-catenin/Tcf4 on P-gp expression. NCI/ADR-RES cells were exposed to FH535, β-catenin/Tcf4 inhibitor in 5% FBS medium for 24 hr.
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on the GEMs activates cSrc kinase and β-catenin signal-
ing; nuclear β-catenin with Tcf4 binds to the MDR1 pro-
moter and upregulates MDR1 expression. Increase of P-
gp extrudes anticancer drug out of cells and leads to can-
cer resistance. Conversely, MBO-asGCS silences GCS
gene and down-regulates P-gp through decreasing cSrc
and β-catenin signaling.
Conclusions
This study demonstrates, for the first time, that GCS
upregulates MDR1 expression and modulates drug resis-
tance of cancer. GSLs, in particular of globo series GSLs
mediate gene expression of MDR1 through cSrc and β-
catenin signaling.
Methods
Cell culture
Drug-resistant NCI/ADR-RES human ovarian cancer
cells (designed as MCF-7-AdrR previously) [63,64] were
kindly provided by Dr. Kenneth Cowan (UNMC Eppley
Cancer Center, Omaha, NE) and Dr. Merrill Goldsmith
(National Cancer Institute, Bethesda, MD, USA). The
ovarian carcinoma cells A2780-AD, which is resistant to
doxorubicin [65], was kindly provided by Dr. Thomas C.
Hamilton (Fox Chase Cancer Center, Philadelphia, PA).
Doxorubicin-selected KB-A1 cells [66] were from Dr.
Michael M. Gottesman (National Cancer Institute,
Bethesda, MD). Drug resistant SW620/Ad colon cancer
cells [67] were kindly provided by Drs. Susan Bates and
Antonio Fojo (National Cancer Institute, Bethesda, MD).
Drug-resistant murine EMT6/AR1 breast carcinoma cells
[68,69] were kindly provided by Dr. Ian Tannock (Ontario
Cancer Institute, Toronto, ON, Canada). The OVCAR-8
human ovarian carcinoma cells were provided by Dr. M.
Hollingshead of Division of Cancer Treatment and Diag-
nosis Tumor Repository at National Cancer Institute
(Frederick, MD). NCI/ADR-RES, KB-A1 and SW620Ad
cells were maintained in RPMI-1640 medium containing
10% (v/v) FBS, 100 units/ml penicillin, 100 μg/ml strepto-
mycin, and 584 mg/liter L-glutamine. A2780-AD cells
were cultured in RPMI-1640 medium containing 100 nM
doxorubicin in addition to the above components.
EMT6/AR1 cells were maintained in Dulbecco's modified
eagle medium (DMEM) containing 1 μg/ml of doxorubi-
cin for 2 days/week in addition to the above components.
Cells were cultured in a humidified incubator with 95%
air and 5% CO2 at 37°C. Doxorubicin hydrochloride was
purchased from Sigma (St. Luis, MO). NCI/ADR-RES
cells transfected with human GCS gene (NCI/ADR-RES/
GCS) and GCS antisense (NCI/ADR-RES/asGCS) were
cultured in RPMI 1640 containing the above components
and G418 (400 μg/mL) [13,70].
Mixed-backbone oligonucleotide and inhibitors
A mixed-backbone oligonucleotide, designed to target
the ORF 18-37 of human GCS [34,71], was verified and
designated as MBO-asGCS [35]. MBO-asGCS were 20-
mer phosphorothioate DNAs, except that four bases at
the 5' end and the 3' end were replaced by 2'-O-methyl
RNA. MBO-asGCS was synthesized and purified by
reverse-phase HPLC and desalting (Integrated DNA
Technologies, Inc., Coralville, IA). The MBO-asGCS was
introduced into cells with Lipofectamine™ 2000 (Invitro-
gen, Carlsbad, CA) in Opti-MEM I reduced-serum
medium (Invitrogen). To repress MDR1 expression, cells
were transfected with MBO-asGCS (100 nM) twice and
grown in 10% FBS RPMI-1640 medium for 7 days. To
inhibit P-gp function, NCI/ADR-RES cells were exposed
Figure 9 GSL Synthesis and MDR1 Expression. GCS, glucosylceramide synthase; GlcCer, glucosylceramide; Tcf4, T-cell factor 4; FAK, focal adhesion 
kinase; cSrc, proto-oncogene (Schmidt-Ruppin A-2); Gb3, globotriaosylceramide; Gb5, globopentaosylceramide; MSGb5, monosyl-Gb5.
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to verapamil (10 μM) in 5% RPMI-1640 at 37°C for 2 hr,
before the analysis of accumulation and efflux. Verapamil
hydrochloride was purchased from Sigma-Aldrich (St.
Louis, MO).
To silence Gb3 synthase, NCI/ADR-RES and NCI/
ADR-RES/GCS cells were transfected with siRNA target-
ing human Gb3 synthase (siRNA-Gb3S 100 nM) or
scrambled control siRNA (siRNA-SC 100 nM) twice and
grown in 10% FBS RPMI-1640 medium for 7 days. The
siRNA targeting human Gb3 synthase and control
siRNA-A were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). β-1,3-Gal-TL siRNA (sc-
62006) was designed to knockdown human β-1,3-galac-
tosyltransferase (GeneID: 145173). Control siRNA-A was
consists of a scrambled sequence that will not lead to the
specific degradation of Gb3. siRNAs (100 nM) were
introduced into these cells with Lipofectamine 2000.
A Src kinase inhibitor, 4-amino-5-(4-chlorophenyl)-7-
(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) [37,38] was
purchased from Enzo Life Sciences (Plymouth Meeting,
PA). An effective β-catenin/Tcf inhibitor, FH535 [45] was
purchased from Sigma-Aldrich (St. Louis, MO). OVCAR-
8/GCS cells were incubated with PP2 (10 μM) in 5%
RPMI-1640 medium for 24 hr. NCI-ADR-RES cells were
exposed to FH535 (1 to 20 μM) in 5% RPMI-1640
medium for 24 hr.
Western blotting analysis
Western blotting was conducted as described previously
[13,17]. After treatments, cells or tissue homogenates
were lysed using NP40 cell lysis buffer (Biosource, Cama-
rillo, CA, US) to extract the total cellular protein for
Western blot. The nuclear proteins were extracted as
described previously [72]. Briefly, cells were suspended in
100 μl of Tween-20 lysis buffer (25 mM Tris/Hepes, pH
8.0, 250 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsul-
fonyl fluoride, 0.5% Tween-20), and kept on ice for 15
min. The nuclei were pelleted at 6000 g for 5 min at 4°C,
and then resuspended in 100 μl of the lysis buffer con-
taining 500 mM NaCl and incubated on ice for additional
15 min. After incubation, the samples were mixed with
100 μl of the lysis buffer (without NaCl). The supernants
were collected for Western blotting following a spin-
down at 10,000 g for 15 min. Equal amounts of these pro-
teins (50 μg/lane) were resolved using 4-20% gradient
SDS-PAGE (Invitrogen). The transferred blot was
blocked with 5% fat-free milk in PBS and immuno-blot-
ted with primary antibodies (anti-GCS goat IgG, anti-P-
pg mouse, cSrc, phosphorylated cSrc, phosphorylated
FAK, β-catenin, phosphorylated β-catenin) at 4°C, over-
night. The antigen-antibody in blots was detected by
using a second antibody-conjugated HRP and enzyme-
linked chemiluminescence plus substrate (GE Health-
care). GAPDH or β-tubulin was used as loading control
for total proteins or nuclear proteins.
Immunohistochemistry
Cells (10,000 cells/chamber) were grown in 4-chamber
slides with 10% FBS culture medium for 48 hr. After
methanol fixation, cells were blocked and then incubated
with anti-GCS serum and anti-P-gp antibody (1:100) in
block solution (Vector Laboratories, Burlingame, CA),
overnight at 4°C. GCS antibody and P-gp antibody on
cells were recognized by Alexa Fluor®488 goat anti-rabbit
IgG and Alexa Fluor 667 goat anti-mouse IgG (Invitro-
g e n).  C e ll  n u cl e i we r e  c ou n t e rs tai ned wit h D API ( 4',  6
diamidino-2-phenylindole) in mounting solution (Vector
Laboratories). The slides were observed using a Nikon
TE-2000 phase contrast microscope, and the images were
captured by a Retiga 2300™ monochrome digital camera
using IPLab™ image analysis program (Scanalytics Inc.,
Rockville, MD).
Cell viability assay
Cell viability was analyzed by quantitation of ATP, an
indicator of active cells using CellTiter-Glo luminescent
cell viability assay (Promega, Madison, WI), as described
previously [17]. Briefly, cells (4,000 cells/well) were grown
in 96-well plates with 10% FBS RPMI-1640 medium for
24 hr. MBO-asGCS (50 nM) was introduced into cells by
Lipofectamine 2000 (vehicle) in Opti-MEM reduced-
serum medium, for 4 hr. Cells were then incubated with
increasing concentrations of agents in 5% FBS medium
for another 72 hr. Cell viability was determined by the
measurement of luminescent ATP using a Synergy HT
microplate reader (BioTek, Winnooski, VT. USA), follow-
ing incubation with CellTiter-Glo reagent (Promega,
Madison, WI, USA).
Verocytotoxin was kindly provided by Dr. Clifford A.
Lingwood (University of Toronto and Hospital for Sick
Children, Toronto, Canada). After 24 hr growth in 96-
well plates, cells were incubated with verocytotoxin in 5%
FBS RPMI-1640 medium for an additional 72 hr.
Cellular ceramide glycosylation assay
Cells were grown 24 hr in 35-mm dishes (1 × 106 cells/
dish) in 10% FBS RPMI-1640 medium and MBO-asGCS
(50 nM) was introduced as described above. After 12 hr
growth in 10% RPMI-1640 medium, cells were switched
to 1% bovine serum albumin (fatty acid free) medium
containing 50 μM NBD C6-ceramide complexed to BSA
(Invitrogen). After 2 hr incubation at 37°C, lipids were
extracted, and resolved on partisil high performance TLC
plates with fluorescent indicator in a solvent system con-
taining chloroform/methanol/3.5 N ammonium hydrox-
ide (85:15:1, v/v/v), as described previously [17,73]. NBD
C6-glucosylceramide and NBD C6-ceramide were identi-Liu et al. Molecular Cancer 2010, 9:145
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fied using AlphaImager HP imaging system (Alpha Inno-
tech, San Leandro, CA) and quantitated on a Synergy HT
multi-detection microplate reader (BioTek). For quantita-
tion, calibration curves were established after TLC sepa-
ration of NBD C6-ceramide (Invitrogen) and NBD C6-
glucosylceramide (N-hexanol-NBD-glucosylceramide;
Matreya, Pleasant Gap, PA).
Glycosphingolipid analysis
Cells were cultured in 10% FBS RPMI-1640 medium and
harvested by trypsin-EDTA. Approximately 400 mg of
pelleted cells was lyophilized and extracted twice with 4
ml of chloroform/methanol (2/1, v/v). The two extracts
were combined, evaporated to dryness and subjected to
saponification by suspending the residue in 1 ml of 0.5 N
NaOH. After incubation at 55°C for 1 hr, the mixture was
neutralized with glacial acetic acid, evaporated to dry-
ness, suspended in 1 ml of water, exhaustively dialyzed
against water and lyophilized. The lyophilized powder
was dissolved in 100 μl chloroform/methanol (2/1) and a
5-μl aliquot was spotted on a TLC plate (Merck, Darm-
stadt, Germany). The plate was developed in chloroform/
methanol/12 mM MgCl2  (50/40/10, v/v/v), and GSLs
were visualized by spraying the plate with diphenylam-
ine-aniline phosphoric acid reagent as described previ-
ously [74].
GSLs on GEMs were prepared and analyzed in NCI/
ADR-RES/asGCS, OVCAR-8/GCS and each mock-trans-
fected cell lines, as described previously [58,75] with
modification. Briefly, cells (1 × 107) were harvested, sus-
pended in 1 ml of lysis buffer containing 1% Triton X-100
(TX-100), and 75 units of Aprotinin in TNEV solution (10
mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1
mM NaVO4), homogenized and incubated on ice for 20
min. Cell lysates were centrifuged for 5 min at 1300 g to
remove nuclei and large cellular debris. The supernatant
collected (700 μl) was mixed with equal volume (700 μl)
of 85% sucrose (wt/vol) in TNEV solution. The diluted
Triton X-100 lysates were overlaid with 30% (6 ml) and
5% (3.3 ml) of sucrose TNEV solution in SW41 centrifuge
tube. The samples were centrifuged for 18 h at 200,000 g
at 4°C. White bands located at ~5-7% sucrose were col-
lected as GEM fraction and its protein content was deter-
mined using BCA Protein Assay Kit. The lipids were
extracted with chlofrom/methanol/water (1:1:1, v/v/v)
from 200 μg of GEM protein. Extracted lipids were resus-
pended in choloform-methanol (1:1, v/v) and applied to
partisil HPTLC plates. Lipids were resolved using the sol-
vent system of chloroform/methanol/water (65:25:4 v/v/
v). Acid alcohol (90% methanol/5% sulfuric acid, 5% ace-
tic acid; Sigma-Aldrich) was used for the chemical detec-
tion of glycosphingolipids. Neurtral glycospingolipids
qualmix and ceramide trihexosides (Gb3) were purchased
from Matreya (Pleasant Gap, PA) and used as standards
in TLC.
High-pressure liquid chromatography (HPLC) analysis of 
doxorubicin
The concentrations of doxorubicin in cells, serum and
tumors were analyzed, as described previously with
minor modifications [76,77]. Cells (2.5 × 105 cells/well)
were grown in 6-well plates with 10% FBS RPMI-1640
medium. After 24 hr, cells were shifted to medium con-
taining doxorubicin (100 μM) for 2 hr incubation, at
37°C. Following ice-cold PBS rinsing, cellular doxorubicin
was extracted using 3 ml of methanol. For tumor samples,
~80 mg of tissue was homogenized in 200 μl of ice-cold
methanol. After centrifugation (7,000 g, 10 min), the
supernatant of samples was injected into the HPLC sys-
tem with an auto-sampler. Doxorubicin was resolved on a
Pecosphere C18 reversed-phase column with mobile
phase of 50 mM sodium phosphate buffer (pH 2.0):ace-
tonitrile:1-propanol (65:25:2; v/v/v; flow rate of 0.8 ml/
min). Doxorubicin was detected with the use of a scan-
ning fluorescence detector at λexcitation  480 nm and
λemission 550 nm. The retention time was approximately 7
minutes for doxorubicin. Standard curves were linear
within the range of 1 ng/ml to 100 ng/ml (equal to 0.002 ~
0.17 μM). Samples containing high doxorubicin concen-
trations were diluted as needed.
For the analysis of doxorubicin in serum, proteins were
precipitated with 10% trichloroacetic acid. The superna-
tant obtained after centrifugation (7,000 g, 10 min) was
used for HPLC assay.
Paclitaxel accumulation and efflux
The measurements were performed as described previ-
ously [78,79]. After treatments or transfection, cells were
grown in 10% FBS RPMI-1640 medium for 24 hr and then
shifted to 5% FBS RPMI-1640 medium containing Flu-
otax-2 (Oregon green 488 paclitaxel, 0.5 μM) and incu-
bated at 37°C for 2 hr. After ice-cold wash and
trypsinization, accumulation of paclitaxel was measured.
For efflux, at the end of the 2 hr incubation, fresh media
was added following wash and re-incubated at 37°C for
an additional 2 hr. Fluorescent paclitaxel was measured at
λexcitation 485 nm and λemission 529 nm using a Synergy HT
microplate reader. Cellular accumulation of paclitaxel
was normalized to cell number and paclitaxel added
(total intensity). The efflux was normalized against accu-
mulated paclitaxel in cells. Flutax-2 (Oregon green 488
paclitaxel) was purchased from Invitrogen.
After two MBO-asGCS administrations (1 mg/kg every
3-days, ip, 3 mice/group), the small intestine (ileum) and
tumors were resected. Tissues (25 mg/reaction) were
incubated with fluorescent paclitaxel (1.0 μM) in 200 μl ofLiu et al. Molecular Cancer 2010, 9:145
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1% BSA RPMI-1640 medium containing collagenase IV,
immediately following mincing. Accumulation of pacli-
taxel was measured after 2 hr incubation and 3 times of
washes with ice-cold PBS. For efflux, samples were incu-
bated with fresh medium for an additional 2 hr following
accumulation and washed 3 times with ice-cold PBS.
Drug-resistant tumor models and treatments
Drug-resistant NCI/ADR-RES tumors were established
by using the methods described previously [35,80]. Athy-
mic nude mice (Foxn1nu/Foxn1+, 4-5 weeks, female) were
purchased from Harlan (Indianapolis, IN) and main-
tained in the Vivarium, University of Louisiana at Mon-
roe, according to the approved protocol. Cultured cells
after 3 to 5 passages were washed with and resuspended
in serum-free RPMI-1640 medium. A suspension of NCI/
ADR-RES cells (1 × 106 cells in 20 μl per mouse) was
injected into the left flank of the mouse. The mice were
monitored by measuring tumor growth, body weight and
clinical observation. Tumor-bearing mice were randomly
divided into multiple treatment and control groups (ten
mice per group). MBOs, dissolved in RPMI 1640 medium
were given at the dose of 1 mg/kg, twice per week, at the
tumor site. The control group received medium only. In
combination therapy, doxorubicin was given by intraperi-
toneal injection at 2 mg/kg once a week with medium or
MBOs for 42 days, respectively.
Tumors were removed, fixed and maintained in paraf-
fin blocks. Microsections from each tumor (5 μm) were
H&E stained and identified by pathologist (Dr. J. Bao).
For immunostaining, antigens were retrieved in steaming
sodium citrate buffer (10 mM, 0.05% Tween-20, pH 6.0,
10 min). After blocking with 2% block solution (Vector
Laboratories, Burlingame, CA), the slides were incubated
with primary antibodies (1:100) at 4°C, overnight.
MDR1 promoter assay
The human MDR1 promoter reporter, pMDR1 [81] was
kindly provided by Dr. Kathleen W. Scotto (University of
Medicine and Dentistry of New Jersey, New Brunswick,
NJ).  MDR1  promoter (sequence from -1202 to +118)
drives luciferase expression from pGL2B. After treat-
ments or transfection, cells (2.5 × 105 cells/well) were
placed into 6-well plates with 10% FBS RPMI-1640
medium. After 24 hr culture, pMDR1 plasmid (4 μg/well)
and pGL4 renilla luciferase reporter driven by thymidine
kinase promoter (pGL4-hRluc/TK; 4 μg/well) were intro-
duced into cells with Lipofectamine 2000 and cells were
cultured in 10% FBS medium for additional 48 hr. Cell
lysates were incubated with Dual-luciferase reporter
assay system reagents (Promega). The intensities of firefly
luciferase (MDR1  promoter activity) and renilla
luciferase (TK promoter activity) were measured using a
Synergy HT multidetection microplate reader. MDR1
promoter activity was normalized to protein and TK pro-
moter.
Statistic analysis
All data represent the mean ± SD. Experiments in tripli-
cate were repeated 2 or 3 times in cell models. Student's t
test was used to compare mean values, using a Prism 4
program (GraphPad software, San Diego, CA).
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